N/A N=164 Extracardiac Complications After Cardiac Surgery
Acute Lung Injury · Sepsis · Infections
Primary: Acute Lung Injury After Cardiac Surgery — 20 participants — p=<0.05
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
N/A N=96 Remote Ischemic Preconditioning in ad Hoc Percutaneous Coronary Interventions
Coronary Artery Disease
Primary: Delta Cardiac Troponin I (ΔcTnI) — 0.04; 0.19 ng/mL
N/A N=336 Assessment of Myocardial Ischemic-Reperfusion Injury During Off- and On- Pump CABG
Ischemic Heart Disease · Coronary Artery Disease · Ischemic Reperfusion Injury
Primary: Myeloperoxidase — 184.3; 66.5; 144.71 g/L
Phase 4 N=50 Safety of Argatroban Infusion in Conduction Disturbances
Stable Coronary Artery Disease (CAD) · Unstable Angina (Troponin Negative)
Primary: Mean Difference in QTc Interval Between ECG-2 and ECG-1 (ITT Population) — 0.94 milliseconds
Phase 4 N=314 Effects of Microplegia on Transfusion Rates After Cardiac Surgery
Aortic Valve Disease · Mitral Valve Disease
Primary: Intraoperative and Postoperative Transfusions — 2.43; 2.97; 4.42; 3.50 units of blood per participant — p=0.354
N/A N=983 Safety Assessment of Angioplasty Procedures
Angiospastic; Disorder
Primary: Number of Major Adverse Cardiac Events (MACE) — 9; 6; 2; 119 Participants
N/A N=434 VAscular Closure for Cardiac Ablation Registry (VACCAR)
Atrial Fibrillation
Primary: Hemostasis — 9; 20; 7 minutes
N/A N=439 Evaluation Of New Onset Postoperative Atrial Fibrillation
Atrial Fibrillation New Onset
Primary: Primary Safety Endpoint — 3.9; 3.6 percentage of participants
N/A N=1,744 REPLACE: Implantable Cardiac Pulse Generator Replacement Registry
Device Replacement · Elective Replacement (ERI) · Device Advisory
Primary: Percentage of Subjects Experiencing a Complication During Generator Replacement Without a Planned Lead Revision or Addition (Straight-forward Device Replacment) or With…
N/A N=460 Cerebral Autoregulation Monitoring During Cardiac Surgery
Thoracic Surgery · Cardiopulmonary Bypass
Primary: Composite Neurological Outcome of Clinical Stroke or New Ischemic Brain Lesion on Diffusion Weighted MRI or Neurocognitive Dysfunction 4 to 6 Weeks After Surgery. — 79…
N/A N=109 Comparison of Percutaneous Closure to Manual Compression for Hemostasis
Atrial Fibrillation
Primary: Time to Hemostasis — 4.5; 10.7 seconds
Phase 2 N=448 Myocardial Protection With Multiport Antegrade Cold Blood Cardioplegia
Coronary Artery Bypass Surgery
Primary: Post-op CK-MB Levels — 71.70; 92.66 IU/L — p=<0.05
Phase 4 N=208 Thromboaspiration in Patients With High Thrombotic Burden Undergoing Primary Percutaneous Coronary Intervention (PCI)
Primary PCI for STEMI
Primary: Rate of Complete ST-segment Elevation Resolution at 60 Minutes After the End of the Procedure — 38; 58 Participants
N/A N=47 Synchronized Cardiac Assist for Cardiogenic Shock
Shock, Cardiogenic · High Risk Percutaneous Coronary Interventions
Primary: Number of Participants With Device and Procedure Related Serious Adverse Events — 11; 5 Participants
Phase 3 N=882 Levosimendan in Patients With Left Ventricular Systolic Dysfunction Undergoing Cardiac Surgery On Cardiopulmonary Bypass
Coronary Artery Bypass Grafting · Mitral Valve Surgery · Low Cardiac Output Syndrome
Primary: Number of Dual Efficacy Endpoint Events — 56; 48 events
N/A N=483 Perioperative Management of Patients With Coronary Stents Undergoing Noncardiac Surgery
Acute Coronary Syndrome · Coronary Stent Occlusion · Surgery
Primary: Major Adverse Cardiac and Cerebrovascular Events (MACCEs) — 63 participants
N/A N=60 Prophylactic Maze to Prevent Atrial Fibrillation in Adult Cardiac Surgery
Coronary Artery Disease
Primary: Incidence of Documented Post-operative Atrial Fibrillation — 17; 2 Participants
N/A N=20 Percutaneous Hemodynamic Support With Impella 2.5 During Scar-related Ventricular Tachycardia Ablation
Ventricular Tachycardia
Primary: Number of Participants With Procedural Success — 8; 6 Participants
N/A N=5,179 International Study of Comparative Health Effectiveness With Medical and Invasive Approaches (ISCHEMIA)
Cardiovascular Diseases · Coronary Disease · Coronary Artery Disease
Primary: Primary Composite Outcome: Death From Cardiovascular Causes, Myocardial Infarction, or Hospitalization for Unstable Angina, Heart Failure, or Resuscitated Cardiac Arrest…
Phase 1 N=6 Utilization of Confocal Microscopy During Cardiac Surgery
Atrial Septal Defect
Primary: Number of Participants Who Experienced Adverse Events Possibly Related to Study Intervention — 0; 6 Participants
N/A N=8 Continuous Cardiac Arrhythmia Monitoring in Hemodialysis Patients
Arrhythmias, Cardiac
Primary: Number of Participants With a Significant Arrhythmia Detected — 0 participants
Phase 4 N=280 Anti-inflammatory Effects of Colchicine in PCI
Coronary Artery Disease
Primary: Percent Change in Post-procedural IL-6 Concentration From Baseline to 30 Min -1 hr After PCI — 0; 20 % change — p=0.31
Phase 2 N=100 Safety of PZ-128 in Subjects Undergoing Non-Emergent Percutaneous Coronary Intervention
Arterial Occlusive Diseases · Coronary Artery Disease · Coronary Disease
Primary: First Occurrence of Major Plus Minor Thrombolysis in Myocardial Infarction (TIMI) Bleeding Events; Number/Percentage of Observed Participants With Outcome Measure Events…
N/A N=75 Caring for the Radial Artery Post-angiogram
Transradial Angiogram
Primary: Bleeding Requiring Intervention After Initial Hemostasis Achieved — 2; 6; 3 participants — p=0.25
N/A N=100 Randomized Study of the Use of Warfarin During Pacemaker or ICD Implantation in Patients Requiring Long Term Anticoagulation
Bradycardia · Tachycardia · Atrial Fibrillation
Primary: Bleeding Complication — 0; 2; 0; 2 participants
N/A N=29 Proteolytic Enzyme Induction Within the Human Myocardial Interstitium
Heart Disease
Primary: Pulmonary Vascular Resistance — 153.8; 213.0; 174.6; 123.5 dyne*second/centimeter˄5 — p=<0.05
Phase 2 N=205 Remote Ischemic Preconditioning Prior to Vascular Surgery
Peripheral Arterial Disease · Vascular Surgery
Primary: Troponin I Elevation Above the Upper Reference Limit (URL) — 25; 22 participants
Phase 4 N=70 Pilot - Peri-operative Beta Blockade
Adrenergic Beta-Receptor Blockader · Troponin Levels · Cardiomyopathy, Post-surgical
Primary: Difference in hscTnI Values — 3.4; 2.8 ng/L
N/A N=80 Genetic Determinants of the Coronary Microvascular Obstruction in PCI
Myocardial Infarction · No-Reflow Phenomenon
Primary: Hospital Mortality Rate — 6; 2 Participants
Phase 2 N=33 Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of MDCO-2010 in Patients Undergoing Elective Coronary Artery Bypass Graft Surgery
Coronary Artery Bypass Graft · Cardiopulmonary Bypass
Primary: Incidence of Adverse Events — 3; 3; 5; 4 participants